Rakuten Aspyrian Inc.'s $150 million from its series C round will fuel a near-term phase III trial and more with ASP-1929, a light-activated antibody drug conjugate (ADC), CEO Miguel Garcia-Guzman told BioWorld. "Probably by mid-next year, we'll be running ASP-1929 in head and neck cancer plus three additional [oncology] indications," he said, adding that the new capital "will not be able to finance everything toward the market," and the ambitious firm will seek more as needed.